|
|
| |
 |
|
 |
| |
| |
| IsoTherapeutics
Group, LLC |
 |
| Radiopharmaceutical R&D
and Consulting |
|
|
|
|
|
|
|
| ITG Staff |
| |
|
R. Keith Frank, Ph.D.
|
Dr. Frank is President,
Chief Executive Officer, and co-founder of ITG. A synthetic
organic chemist by training, he has spent the first 23 years of
his career at The Dow Chemical Company. His principle
activity was in the development of radiopharmaceuticals,
including two approved products (Quadramet® and
125I-IotrexTM). He holds 22 US patents and
has over 30 publications.
Dr. Frank initiated and led ChelaMedSM
radiopharmaceutical services at Dow. In that role he helped
other companies develop radiopharmaceuticals and taught them
about isotopes and conjugation chemistry. He also has
expertise in developing tumors in animal studies and in radiation
dosimetry.
Complete CV  |
| |
|
Jaime (Jim) Simón, Ph.D. |
Dr. Simón is Vice
President, Chief Scientific Officer, and co-founder of ITG. He is
a radiochemist by training and spent 25 years at Dow where he was
responsible for a group dedicated to developing new
pharmaceutical technologies. He holds over 50 US patents,
including the key patents covering Quadramet®
(153Sm-EDTMP) for the treatment of bone cancer and STR
(166Ho-DOTMP) for safely ablating bone marrow prior to
bone marrow transplants. Dr Simón has over 70 publications.
Complete CV
|
Alan D. Strickland, M.D., Ph.D. |
Dr. Strickland is Chief
Medical Officer of ITG. He spent the earlier part of his career
as a professor of medicine and in private practice in pediatric
medicine specializing in gastro-enterology. He then earned a
Ph.D. in chemistry and joined The Dow Chemical Company.
In his 15 years at Dow, Dr. Strickland helped to develop
radiopharmaceuticals and developed new therapies to treat end
stage renal disease. In addition Dr. Strickland has experience in
the design and execution of clinical trials. He holds 14 US
patents and has over 30 publications.
Complete CV
|
Prakash "Buck" Bakhru |
Mr. Bakhru serves as
Director of Business Development for ITG. He is a hands-on
product, sales, market and business development professional. Mr.
Bakhru's career includes working for The Dow Chemical
Company, W.L. Gore & Associates, and Honeywell Inc. While
employed by these companies, Mr. Bakhru gained experience in
R&D, manufacturing, technical service, product management,
market development, sales and business management. Among his
several noteworthy accomplishments, he is most proud of leading a
wire and cable product management team to increasing revenue from
$13MM to $30MM in 5 years. Mr. Bakhru has traveled extensively,
both domestically and in Asia Pacific to meet customers and
develop new sales and markets for products. He has MS degree in
Metallurgical Engineering from University of Missouri-Rolla.
Complete CV
|
Jason Rogers |
Mr. Rogers is Laboratory
Manager and Assistant Radiation Safety Officer. He
joined ITG in 2007. Mr. Rogers had prior experience in the
United States Navy as a Machinist's Mate 2nd Class where he
was tasked with the maintenance for all systems dealing with the
nuclear reactor plants on the U.S.S. John C. Stennis (Carrier
Class CVN-74). He was in charge of divisions averaging 10 people
and developed a cataloging and maintenance plan for primary
piping systems.
Complete CV
|
Druce Crump |
Mr. Crump is a Senior
Scientist at ITG. He is a chemist with vast experience in
chelating agents product research & development. He has
patented new compositions and formulations, has experience in
chemical production plant support, customer support, and in
bringing innovative chemistry and engineering ideas successfully
to commercialization
Complete CV
|
George M. St. George, Ph.D. |
Dr. St. George is a
Scientist at ITG. He spent 26 years at The Dow Chemical
Company, specializing in the synthesis of chelating agents and
metal chelates, and in their industrial scale-up. In addition to
over 80 internal Dow research reports, he is the author of nine
US patents and an external journal publication. Additionally, he
is trained in ISO 9000.
Complete CV
|
|
| Scientific Advisory Board |
Wynn A. Volkert, Ph.D. |
Dr. Volkert is the
Director of the Radiopharmaceutical Sciences Institute at the
University of Missouri. Wynn is an icon in radiopharmaceutical
chemistry. He was the main scientist at the University of
Missouri responsible for initiating and developing two products
from concept to commercialization. These include the Tc-99m based
CeretecTM for brain imaging and
Quadramet® for relief of pain in bone metastases.
The latter is based on the rare earth radioisotope Sm-153. In
addition, Wynn has spent the last few years developing new
technologies for labeling peptides. His hard work and expertise
have been key to the development of the Radiopharmaceutical
Sciences Institute at the University of Missouri which boasts a
complete small animal imaging facility.
Complete CV
|
|
Alan R. Fritzberg, Ph.D. |
Dr. Fritzberg is an
Affiliate Associate Professor of Radiology at the University of
Washington. Alan made his mark in nuclear medicine early in his
carrier as an inventor of kidney imaging agents. His work while
at the University of Utah and the University of Colorado led to
the Tc-MAG3 chelates that continue to be used for renal imaging
today. He then founded NeoRx Corporation to develop novel
approaches to treat cancer based primarily on Re-188 and Re-186.
He and his scientific team explored a variety of technologies
which makes him extremely versatile in the field. Among them are
pretargeting technology to improve target to non-target ratio of
antibodies and the development of Ho-166-DOTMP to treat multiple
myeloma.
Complete CV
|
Theresa W. Fossum DVM, MS, PhD; Diplomate, ACVS |
Theresa (Terry) W.
Fossum is a Professor of Surgery and holds the Tom and Joan Read
Chair in Veterinary Surgery at Texas A&M University. She is a
world renowned surgeon and serves as the Director for
Cardiothoracic Surgery and Biomedical Devices in the Michael E.
DeBakey Institute at TAMU. She was recently appointed Director of
the new Texas A & M Institute for Preclinical Studies , a 70
million dollar venture at TAMU which will promote public-private
partnerships to speed the development of medical devices and
drugs. Dr. Fossum’s leadership was integral in
conceptualizing and funding this Institute.
Dr. Fossum sits on the Board of Directors of the National Space
Biomedical Research Institute (NSBRI) and is a member of the
Board of Governors for the Foundation for Biomedical Research
(FBR). Dr Fossum, along with Dr. Michael E. DeBakey, founded the
CARE Foundation in 2004 in order to provide an
infrastructure for veterinary medicine to perform research using
animals with spontaneous disease. Dr. Fossum serves as President
of the organization.
Complete CV
|
Alan R. Ketring, Ph.D. |
Dr. Alan Ketring was
involved in the development of Tc-99m heart agents at the
University of Cincinnati as a postdoctoral fellow in the research
group of Ed Deutsch. Alan then had a brief stent at Mallinkrodt
before becoming a scientist at the University
of Missouri Research Reactor (MURR) In his role at MURR as
director of the Medical Radioisotope Research and Development
program, Alan is very familiar with the production and utility of
a wide variety of radionuclides for both diagnostic and
therapeutic applications. His expertise in the production, use,
safe handling, federal regulations and shipping of radioisotopes
was criticalto the development of Quadramet and other potential
radiopharmaceuticals currently in preclinical and clinical
trials.
Complete CV
|
Lewis A Shadoff, Ph.D. |
Dr. Shadoff is an
analytical chemist. He spent 28 years at The Dow Chemical
Company, specializing in the identification and quantification of
a wide variety of chemical process, environmental, and
pharmaceutical samples. He worked on Quadramet®
during its development by confirming the molecular structure and
also the species produced by radiation damage as part of a study
to assess their potential toxicity. During his tenure at Dow he
achieved the highest rung of their scientific ladder.
He has presented papers at National Chemical Society Meetings,
AAAS National Meetings, International Dioxin Symposiums, and
Italian Chemical Society Meetings. He has over 25 publications in
peer-reviewed scientific journals.
Complete CV
|
David A. Wilson |
Mr. Wilson retired as a
Senior Research Scientist in 2006 after more than 37 years of
service for the Dow Chemical Company. David was instrumental in
commercializing over 30 products during his career, has authored
228 confidential Dow Research Reports, 21 external publications
including the Kirk-Othmer Encyclopedia of Chemical Technology
section on “Chelating Agents”, and is an inventor on
over 100 issued U.S. patents including key patents covering
Quadramet® (153Sm-EDTMP) for the
treatment of bone cancer and STR (166Ho-DOTMP) for
ablating bone marrow prior to bone marrow transplants.
Complete CV
|
|
|
|
|
 |
|
 |
|
|
|
| Designed by:
Elegant Web Templates |
| Copyright© 2006-2009
IsoTherapeutics Group, LLC
Last Update 5 January 2010
|
|
|
|
